Summary
“Plaintiffs are on a winning streak,” said Nora Freeman Engstrom, a professor at Stanford Law School who studies mass tort actions. The recent cases, Ms. Engstrom said, do not bode well for Bayer because plaintiffs’ lawyers can pull statements from prior testimony and build stronger cases over time. “With each trial, the playing field shifts subtly toward plaintiffs,” she added.
Read More